Illumina helped the digital PCR technology developer secure fresh convertible bond and loan financing that will be used for international expansion and the further development of its platform.
France-based DNA quantification technology developer Stilla Technologies has raised €31.3m ($35m) in debt and convertible bond financing from investors including Illumina Ventures, the corporate venturing arm of genomics technology producer Illumina.
The round also featured BNP Paribas Développement, a subsidiary of financial services firm BNP Paribas, as well as LBO France, Eurazeo, Kurma Partners, TusPark Capital Management, Casdin Capital and European Investment Bank. It consisted of $13m in convertible bonds and $22m in loan financing.
Stilla has developed a digital polymerase chain reaction (PCR) platform featuring six fluorescent channels that can be used in liquid biopsy tests for cancer diagnostics as well as cell and gene therapies, infectious diseases, prenatal testing and detection of genetically modified organisms.
The company plans to use the capital to further expand its global commercial presence and develop the next generation of its digital PCR platform.
The deal came after Stilla collected $21.8m in…
